NCT01570205已完成1 期
The Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Male Volunteers in a Randomized, Double Blind, Placebo Controlled, Dose Escalating Phase I Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Xigen SA
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Safety of XG-102
研究概览
简要总结
The objective of the study is to investigate safety, tolerability, and pharmacokinetics of XG-102 following iv infusion of single escalating dose of 10, 40, and 80 µg/kg XG-102 to healthy male volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male volunteers
- •Age ≥ 18 to ≤ 45 years
- •BP: 100 - 150 mm Hg systolic, 50 - 95 mm Hg diastolic and pulse rate: 50 - 100 bpm.
- •Body mass index between 18.5 and 30.0 kg/m2 and body weight in the 50 - 100 kg range.
- •Are able to communicate and co-operate with the Investigator and his/her staff
- •Healthy on the basis of medical history, physical examination findings, clinical laboratory test results, vital sign measurements, and digital 12 lead ECG readings
- •Written informed consent obtained
- •Male subjects with partners of childbearing potential have to use adequate contraception during, and for at least the four weeks after administration of study medication.
排除标准
- •Heavy smokers, i.e. more than 10 cigarettes per day
- •Participation in a clinical trial during the previous 4 weeks
- •Loss of 500 mL blood or more during the 3 month period before the screening visit of the study
- •Existence of any surgical or medical condition which might relevantly interfere with the subject safety, the distribution, metabolism or excretion of the drug or the study assessments, i.e. impaired renal or hepatic function, diabetes mellitus, thyroid function abnormalities including abnormal thyroid hormone values in the Screening evaluation, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.
- •History of alcohol or drug abuse in the last 3 years.
- •Positive results of the drug Screening.
- •Clinically significant abnormal laboratory values at the Screening or baseline evaluation.
- •A history of any serious adverse reaction or hypersensitivity to any drug or other medicines
- •Presence or history of any allergy requiring acute or chronic treatment (seasonal allergic rhinitis which requires no treatment may be tolerated).
- •Positive results from serology examination for HBV, HCV, HIV or tuberculosis
- •History of serious mental disorders.
- •Need of any prescription medication within 30 days prior to the administration of the drug and/or nonprescription medication within 7 days prior to the administration of the drug or anticipated need for any concomitant medication during the study.
- •Volunteers who are unwilling to comply with the provisions of this protocol
- •Symptoms of a significant (upon Investigator's medical judgment) somatic or mental illness in the two week period preceding drug administration.
研究组 & 干预措施
XG-102 10 µg/kg
Experimental
干预措施: XG-102 (Drug)
XG-102 40 µg/kg
Experimental
干预措施: XG-102 (Drug)
XG-102 80 µg/kg
Experimental
干预措施: XG-102 (Drug)
placebo
Placebo Comparator
干预措施: XG-102 (Drug)
结局指标
主要结局
Safety of XG-102
时间窗: 1 month
Safety of XG-102 assessed by incidence and intensity of adverse events, clinical laboratory evaluations, vital signs, ECG, phaysical examination, ocular examination
次要结局
- Pharmacokinetics(16 time-points up to 24 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Single-dose and Multiple-dose X842 Phase 1 StudyHealthy VolunteersNCT04293965Jiangsu Sinorda Biomedicine Co., Ltd80
已完成
1 期
Safety, Tolerability and Pharmacokinetics of XW10508 Immediate and Modified Release Formulations in Healthy AdultsHealthy VolunteersNCT04966832XWPharma84
招募中
1 期
A Phase I Study of XH-S002 in Healthy VolunteersHealthy AdultsNCT06204419S-Infinity Pharmaceuticals Co., Ltd86
已完成
2 期
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's DiseaseMild Cognitive ImpairmentAlzheimer's DiseaseNCT01661673FORUM Pharmaceuticals Inc52
撤回
1 期
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent SubjectsOpioid Withdrawal (Disorder)Opioid Use DisorderNCT06711640USWM, LLC (dba US WorldMeds)16